News25/Ratings8
News · 26 weeks28-60%
2026-04-122026-10-04
Mix1990d
- SEC Filings11(58%)
- Insider7(37%)
- Earnings1(5%)
Latest news
25 items- INSIDERDirector Schwab Andrew J. sold $239,555 worth of shares (148,079 units at $1.62) (SEC Form 4)4 - Skye Bioscience, Inc. (0001516551) (Issuer)
- INSIDERLarge owner 5am Partners Vii, Llc sold $239,555 worth of shares (148,079 units at $1.62) (SEC Form 4)4 - Skye Bioscience, Inc. (0001516551) (Issuer)
- INSIDERDirector Schwab Andrew J. sold $64,734 worth of shares (33,892 units at $1.91) (SEC Form 4)4 - Skye Bioscience, Inc. (0001516551) (Issuer)
- INSIDERLarge owner 5am Partners Vii, Llc sold $64,734 worth of shares (33,892 units at $1.91) (SEC Form 4)4 - Skye Bioscience, Inc. (0001516551) (Issuer)
- SECSEC Form DEFA14A filed by Skye Bioscience Inc.DEFA14A - Skye Bioscience, Inc. (0001516551) (Filer)
- SECSkye Bioscience Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update, Other Events8-K - Skye Bioscience, Inc. (0001516551) (Filer)
- SECSEC Form DEFA14A filed by Skye Bioscience Inc.DEFA14A - Skye Bioscience, Inc. (0001516551) (Filer)
- SECSkye Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Skye Bioscience, Inc. (0001516551) (Filer)
- INSIDERDirector Schwab Andrew J. sold $140,313 worth of shares (375,840 units at $0.37) (SEC Form 4)4 - Skye Bioscience, Inc. (0001516551) (Issuer)
- INSIDERLarge owner 5am Partners Vii, Llc sold $140,313 worth of shares (375,840 units at $0.37) (SEC Form 4)4 - Skye Bioscience, Inc. (0001516551) (Issuer)
- SECSEC Form DEFA14A filed by Skye Bioscience Inc.DEFA14A - Skye Bioscience, Inc. (0001516551) (Filer)
- SECAmendment: Skye Bioscience Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders8-K/A - Skye Bioscience, Inc. (0001516551) (Filer)
- SECSEC Form DEFA14A filed by Skye Bioscience Inc.DEFA14A - Skye Bioscience, Inc. (0001516551) (Filer)
- SECSEC Form 8-K filed by Skye Bioscience Inc.8-K - Skye Bioscience, Inc. (0001516551) (Filer)
- SECSEC Form DEFA14A filed by Skye Bioscience Inc.DEFA14A - Skye Bioscience, Inc. (0001516551) (Filer)
- SECSEC Form 10-Q filed by Skye Bioscience Inc.10-Q - Skye Bioscience, Inc. (0001516551) (Filer)
- SECSkye Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Skye Bioscience, Inc. (0001516551) (Filer)
- PRSkye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in FinancingsCombined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and boardCompany’s lead program will be RXC008, Redx’s GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn’s disease, with an open U.S. IND, FDA Fast Track designation, and a planned Phase 2 clinical studyConcurrent aggregate financings of approximately $125 million committed by a syndicate of new and existing leading healthcare institutional investorsFinancings expected to fund operations through RXC008 Phase 2 clinical trial – topline data expected H2 2028 Companies to hold a joint conference call on August 14, 2026 at 10 a.m. ET SAN DIE
- INSIDERChief Executive Officer Dhillon Punit was granted 1,090,000 shares, increasing direct ownership by 330% to 1,419,823 units (SEC Form 4)4 - Skye Bioscience, Inc. (0001516551) (Issuer)
- SECSkye Bioscience Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Skye Bioscience, Inc. (0001516551) (Filer)
- PRSkye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that the Cohort Review Committee (CRC) responsible for reviewing safety data generated from the CBeyond Part C Expansion Study, and for approving the opening of enrollment in Cohort 2 has unanimously approved opening the second cohort of the CBeyond Part C Expansion study. The CRC focuses exclusively on the safety of the Part C Expansion Study and does not conduct efficacy assessments. The independent Data Monitoring Committee (DMC) continues to have safety over
- SECSEC Form 8-K filed by Skye Bioscience Inc.8-K - Skye Bioscience, Inc. (0001516551) (Filer)
- PRUPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateCBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2 SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones. "Since our March update, execution has focused on turning CBeyond into a Phase 2b-ready development p
- SECSEC Form 10-Q filed by Skye Bioscience Inc.10-Q - Skye Bioscience, Inc. (0001516551) (Filer)
- PRSkye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateCBeyond™ Expansion Study (Part C) initiated; Cohort Review Committee review scheduled for May 18, 2026, to evaluate available safety data and potential progression to Cohort 2Engaged Lilly Catalyze360 to provide strategic guidance on nimacimab TPP and Phase 2b trial design SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones."Sinc
SKYE FAQ
5 questionsWhere does SKYE stock trade?
Skye Bioscience Inc. (SKYE) is listed on NASDAQ.What sector and industry is SKYE in?
Skye Bioscience Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about SKYE?
Skye Bioscience Inc. has had 8 recent analyst actions on file. The most recent action was from Craig Hallum: Hold with a $200.00 price target on 2025-10-06.What companies are similar to SKYE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SKYE side-by-side with any of them on Quantisnow.How can I track SKYE on Quantisnow?
Quantisnow aggregates Skye Bioscience Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SKYE to receive live email and push alerts on every new disclosure.